The US Court of Appeals for the Federal Circuit invalidated yet another set of antibody genus claims, finding the case “materially indistinguishable” from those in the 2023 Supreme Court of the United States case, Amgen v....more
10/5/2023
/ Amgen ,
Amgen v Sanofi ,
Anticipation ,
Appeals ,
Claim Construction ,
Genus ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Patents ,
Sanofi ,
SCOTUS ,
Technology